ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Biomedical Application of Orexin/Hypocretin Receptor Ligands in Neuroscience

View Author Information
Drug Discovery and Preclinical Research & Development, Actelion Pharmaceuticals Ltd., CH-4123 Allschwil, Switzerland
* To whom correspondence should be addressed. Phone: +41 61 565 65 61. Fax: +41 61 565 65 00. E-mail: [email protected]
Cite this: J. Med. Chem. 2009, 52, 4, 891–903
Publication Date (Web):January 20, 2009
https://doi.org/10.1021/jm801296d
Copyright © 2009 American Chemical Society

    Article Views

    3287

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options

    Note: In lieu of an abstract, this is the article's first page.

    Free first page

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 65 publications.

    1. Mathieu Rappas, Ammar A. E. Ali, Kirstie A. Bennett, Jason D. Brown, Sarah J. Bucknell, Miles Congreve, Robert M. Cooke, Gabriella Cseke, Chris de Graaf, Andrew S. Doré, James C. Errey, Ali Jazayeri, Fiona H. Marshall, Jonathan S. Mason, Richard Mould, Jayesh C. Patel, Benjamin G. Tehan, Malcolm Weir, John A. Christopher. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. Journal of Medicinal Chemistry 2020, 63 (4) , 1528-1543. https://doi.org/10.1021/acs.jmedchem.9b01787
    2. David A. Perrey, Ann M. Decker, Yanan Zhang. Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability. ACS Chemical Neuroscience 2018, 9 (3) , 587-602. https://doi.org/10.1021/acschemneuro.7b00402
    3. Hiroshi Nagase, Naoshi Yamamoto, Masahiro Yata, Sayaka Ohrui, Takahiro Okada, Tsuyoshi Saitoh, Noriki Kutsumura, Yasuyuki Nagumo, Yoko Irukayama-Tomobe, Yukiko Ishikawa, Yasuhiro Ogawa, Shigeto Hirayama, Daisuke Kuroda, Yurie Watanabe, Hiroaki Gouda, and Masashi Yanagisawa . Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies. Journal of Medicinal Chemistry 2017, 60 (3) , 1018-1040. https://doi.org/10.1021/acs.jmedchem.6b01418
    4. Lotfi Benmekhbi, Fadila Louafi, Thierry Roisnel, and Jean-Pierre Hurvois . Synthesis of Tetrahydroisoquinoline Alkaloids and Related Compounds through the Alkylation of Anodically Prepared α-Amino Nitriles. The Journal of Organic Chemistry 2016, 81 (15) , 6721-6739. https://doi.org/10.1021/acs.joc.6b01419
    5. Takashi Nagahara, Tsuyoshi Saitoh, Noriki Kutsumura, Yoko Irukayama-Tomobe, Yasuhiro Ogawa, Daisuke Kuroda, Hiroaki Gouda, Hidetoshi Kumagai, Hideaki Fujii, Masashi Yanagisawa, and Hiroshi Nagase . Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. Journal of Medicinal Chemistry 2015, 58 (20) , 7931-7937. https://doi.org/10.1021/acs.jmedchem.5b00988
    6. David A. Perrey, Nadezhda A. German, Ann M. Decker, David Thorn, Jun-Xu Li, Brian P. Gilmour, Brian F. Thomas, Danni L. Harris, Scott P. Runyon, and Yanan Zhang . Effect of 1-Substitution on Tetrahydroisoquinolines as Selective Antagonists for the Orexin-1 Receptor. ACS Chemical Neuroscience 2015, 6 (4) , 599-614. https://doi.org/10.1021/cn500330v
    7. Nadezhda A. German, Ann M. Decker, Brian P. Gilmour, Brian F. Thomas, and Yanan Zhang . Truncated Orexin Peptides: Structure–Activity Relationship Studies. ACS Medicinal Chemistry Letters 2013, 4 (12) , 1224-1227. https://doi.org/10.1021/ml400333a
    8. David A. Perrey, Nadezhda A. German, Brian P. Gilmour, Jun-Xu Li, Danni L. Harris, Brian F. Thomas, and Yanan Zhang . Substituted Tetrahydroisoquinolines as Selective Antagonists for the Orexin 1 Receptor. Journal of Medicinal Chemistry 2013, 56 (17) , 6901-6916. https://doi.org/10.1021/jm400720h
    9. Norihito Oi, Michiyuki Suzuki, Taro Terauchi, Masaki Tokunaga, Yosuke Nakatani, Noboru Yamamoto, Toshimitsu Fukumura, Ming-Rong Zhang, Tetsuya Suhara, and Makoto Higuchi . Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor. Journal of Medicinal Chemistry 2013, 56 (16) , 6371-6385. https://doi.org/10.1021/jm400772t
    10. Ian K. Mangion, Benjamin D. Sherry, Jingjun Yin, and Fred J. Fleitz . Enantioselective Synthesis of a Dual Orexin Receptor Antagonist. Organic Letters 2012, 14 (13) , 3458-3461. https://doi.org/10.1021/ol3014123
    11. Alexander Dömling, Wei Wang, and Kan Wang . Chemistry and Biology Of Multicomponent Reactions. Chemical Reviews 2012, 112 (6) , 3083-3135. https://doi.org/10.1021/cr100233r
    12. Christopher D. Cox, Michael J. Breslin, David B. Whitman, John D. Schreier, Georgia B. McGaughey, Michael J. Bogusky, Anthony J. Roecker, Swati P. Mercer, Rodney A. Bednar, Wei Lemaire, Joseph G. Bruno, Duane R. Reiss, C. Meacham Harrell, Kathy L. Murphy, Susan L. Garson, Scott M. Doran, Thomayant Prueksaritanont, Wayne B. Anderson, Cuyue Tang, Shane Roller, Tamara D. Cabalu, Donghui Cui, George D. Hartman, Steven D. Young, Ken S. Koblan, Christopher J. Winrow, John J. Renger and Paul J. Coleman . Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia. Journal of Medicinal Chemistry 2010, 53 (14) , 5320-5332. https://doi.org/10.1021/jm100541c
    13. Haixia Liu and Alexander Dömling. Efficient and Diverse Synthesis of Indole Derivatives. The Journal of Organic Chemistry 2009, 74 (17) , 6895-6898. https://doi.org/10.1021/jo900986z
    14. Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse. The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of Sleep Research 2023, 32 (6) https://doi.org/10.1111/jsr.13902
    15. Hairong Luo, Meihang Chen, Fen Tian, Yi He, Xurong Liu, Jing Li. An Efficient Method for the Synthesis of N-Aryl Substituted C1-Functionalized 1,2,3,4-Tetrahydroisoquinolines. HETEROCYCLES 2022, 104 (9) , 1641. https://doi.org/10.3987/COM-22-14697
    16. Anas Ansari, Amol B. Gorde, Ramesh Ramapanicker. Asymmetric synthesis of six tetrahydroisoquinoline natural products through α-amination of an aldehyde. Tetrahedron 2021, 88 , 132121. https://doi.org/10.1016/j.tet.2021.132121
    17. Nikolaos P. Tripolitsiotis, Maria Thomaidi, Constantinos G. Neochoritis. The Ugi Three‐Component Reaction; a Valuable Tool in Modern Organic Synthesis. European Journal of Organic Chemistry 2020, 2020 (42) , 6525-6554. https://doi.org/10.1002/ejoc.202001157
    18. Bin Guo, Jingya Xiu, Yi Shen, Qingeng Li. Synthesis and biological activity evaluation of azacycloheptane sulfonamide derivatives as potential orexin receptor antagonists. RSC Advances 2020, 10 (51) , 30683-30691. https://doi.org/10.1039/D0RA05068G
    19. David A. Perrey, Yanan Zhang. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Research 2020, 1731 , 145922. https://doi.org/10.1016/j.brainres.2018.08.025
    20. Dan Zhang, Junwen Liu, Zhenghui Kang, Huang Qiu, Wenhao Hu. A rhodium-catalysed three-component reaction to access C1-substituted tetrahydroisoquinolines. Organic & Biomolecular Chemistry 2019, 17 (46) , 9844-9848. https://doi.org/10.1039/C9OB02303H
    21. Irfan Khan, Jaybir Singh, Vivek Kumar, Ved Prakash Verma, Monika Shukla, Anupam Dhasmana, Puspendera Singh Naruka, Ajay Kumar Goswami, Keshav Lalit Ameta, Shahnawaz Khan. A Versatile Pre and Post Ugi Modification for the Synthesis of Natural Product Inspired Fused Peptide‐Carboline Scaffolds as Potential Anti‐Leishmanial Agents. ChemistrySelect 2019, 4 (42) , 12260-12267. https://doi.org/10.1002/slct.201902441
    22. Naoshi Yamamoto, Sayaka Ohrui, Takahiro Okada, Masahiro Yata, Tsuyoshi Saitoh, Noriki Kutsumura, Yasuyuki Nagumo, Yoko Irukayama-Tomobe, Yasuhiro Ogawa, Yukiko Ishikawa, Yurie Watanabe, Daichi Hayakawa, Hiroaki Gouda, Masashi Yanagisawa, Hiroshi Nagase. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor. Bioorganic & Medicinal Chemistry Letters 2017, 27 (17) , 4176-4179. https://doi.org/10.1016/j.bmcl.2017.07.011
    23. Bibia Heidmann, John Gatfield, Catherine Roch, Alexander Treiber, Simone Tortoioli, Christine Brotschi, Jodi T. Williams, Martin H. Bolli, Stefan Abele, Thierry Sifferlen, François Jenck, Christoph Boss. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold‐Hopping Approach. ChemMedChem 2016, 11 (19) , 2132-2146. https://doi.org/10.1002/cmdc.201600175
    24. Brennon R. Luster, Francisco J. Urbano, Edgar Garcia-Rill. Intracellular mechanisms modulating gamma band activity in the pedunculopontine nucleus (PPN). Physiological Reports 2016, 4 (12) , e12787. https://doi.org/10.14814/phy2.12787
    25. Christoph Boss, Catherine Roch. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934). Expert Opinion on Therapeutic Patents 2016, 26 (3) , 409-415. https://doi.org/10.1517/13543776.2016.1124087
    26. Christopher Hulme, Muhammad Ayaz, Guillermo Martinez‐Ariza, Federico Medda, Arthur Shaw. Recent Advances in Multicomponent Reaction Chemistry. 2015, 145-187. https://doi.org/10.1002/9781118771723.ch6
    27. Brennon Luster, Stasia D'Onofrio, Francisco Urbano, Edgar Garcia-Rill. High-threshold Ca 2+ channels behind gamma band activity in the pedunculopontine nucleus (PPN). Physiological Reports 2015, 3 (6) , e12431. https://doi.org/10.14814/phy2.12431
    28. Christoph Boss. Orexin receptor antagonists – a patent review (2010 to August 2014). Expert Opinion on Therapeutic Patents 2014, 24 (12) , 1367-1381. https://doi.org/10.1517/13543776.2014.978859
    29. Christoph Boss, Catherine Roch‐Brisbare, Michel A. Steiner, Alexander Treiber, Hendrik Dietrich, Francois Jenck, Markus von Raumer, Thierry Sifferlen, Christine Brotschi, Bibia Heidmann, Jodi T. Williams, Hamed Aissaoui, Romain Siegrist, John Gatfield. Structure–Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT‐462206: a Potent, Brain‐Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist. ChemMedChem 2014, 9 (11) , 2486-2496. https://doi.org/10.1002/cmdc.201402258
    30. Yu Yoshida, Taro Terauchi, Yoshimitsu Naoe, Yuji Kazuta, Fumihiro Ozaki, Carsten T. Beuckmann, Makoto Nakagawa, Michiyuki Suzuki, Ikuo Kushida, Osamu Takenaka, Takashi Ueno, Masahiro Yonaga. Design, synthesis, and structure–activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists. Bioorganic & Medicinal Chemistry 2014, 22 (21) , 6071-6088. https://doi.org/10.1016/j.bmc.2014.08.034
    31. Laura H Jacobson, Gabrielle E Callander, Daniel Hoyer. Suvorexant for the treatment of insomnia. Expert Review of Clinical Pharmacology 2014, 7 (6) , 711-730. https://doi.org/10.1586/17512433.2014.966813
    32. John A Christopher. Small-molecule Antagonists of the Orexin Receptors. Pharmaceutical Patent Analyst 2014, 3 (6) , 625-638. https://doi.org/10.4155/ppa.14.46
    33. N. Siva Senkar Reddy, B.V. Subba Reddy. Stereoselective total synthesis of almorexant. Tetrahedron Letters 2014, 55 (20) , 3157-3159. https://doi.org/10.1016/j.tetlet.2014.03.130
    34. Daniel Hoyer, Laura H. Jacobson. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?. Neuropeptides 2013, 47 (6) , 477-488. https://doi.org/10.1016/j.npep.2013.10.009
    35. Thierry Sifferlen, Ralf Koberstein, Emmanuelle Cottreel, Amandine Boller, Thomas Weller, John Gatfield, Catherine Brisbare-Roch, Francois Jenck, Christoph Boss. Structure–activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2. Bioorganic & Medicinal Chemistry Letters 2013, 23 (13) , 3857-3863. https://doi.org/10.1016/j.bmcl.2013.04.071
    36. Thierry Sifferlen, Ralf Koberstein, Emmanuelle Cottreel, Amandine Boller, Thomas Weller, John Gatfield, Catherine Brisbare-Roch, Francois Jenck, Christoph Boss. Synthesis, structure–activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1. Bioorganic & Medicinal Chemistry Letters 2013, 23 (7) , 2212-2216. https://doi.org/10.1016/j.bmcl.2013.01.088
    37. John A Christopher, Miles S Congreve. Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692). Expert Opinion on Therapeutic Patents 2013, 23 (2) , 273-277. https://doi.org/10.1517/13543776.2013.749240
    38. Marc Laburthe, Thierry Voisin. Orexins (Hypocretins). 2013, 541-547. https://doi.org/10.1016/B978-0-12-385095-9.00074-9
    39. L.I. Belen’kii, Yu. B. Evdokimenkova. The Literature of Heterocyclic Chemistry, Part XI, 2008–2009. 2013, 195-290. https://doi.org/10.1016/B978-0-12-404598-9.00003-1
    40. Scott D. Kuduk, Christopher J. Winrow, Paul J. Coleman. Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders. 2013, 73-87. https://doi.org/10.1016/B978-0-12-417150-3.00006-5
    41. John A Christopher. Orexin Receptor Antagonists. Pharmaceutical Patent Analyst 2012, 1 (3) , 329-346. https://doi.org/10.4155/ppa.12.27
    42. Rong Jiang, Xinyi Song, Purva Bali, Anthony Smith, Claudia Ruiz Bayona, Li Lin, Michael D. Cameron, Patricia H. McDonald, Paul J. Kenny, Theodore M. Kamenecka. Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2012, 22 (12) , 3890-3894. https://doi.org/10.1016/j.bmcl.2012.04.122
    43. Octavian C Ioachimescu, Ali A El-Solh. Pharmacotherapy of insomnia. Expert Opinion on Pharmacotherapy 2012, 13 (9) , 1243-1260. https://doi.org/10.1517/14656566.2012.683860
    44. Pilar Menendez, Ilaria D'Acquarica, Giuliano Delle Monache, Francesca Ghirga, Andrea Calcaterra, Marco Barba, Alberto Macone, Alberto Boffi, Alessandra Bonamore, Bruno Botta. Production of Bioactives Compounds: The Importance of Pictet–Spengler Reaction in the XXI Century. 2012, 453-487. https://doi.org/10.1002/9781118260005.ch13
    45. Fei Liu, Vattoly J. Majo, Jaya Prabhakaran, John Castrillion, J. John Mann, Diana Martinez, J.S. Dileep Kumar. Radiosynthesis of [11C]BBAC and [11C]BBPC as potential PET tracers for orexin2 receptors. Bioorganic & Medicinal Chemistry Letters 2012, 22 (6) , 2172-2174. https://doi.org/10.1016/j.bmcl.2012.01.114
    46. Marc Laburthe, Thierry Voisin. The orexin receptor OX 1 R in colon cancer: a promising therapeutic target and a new paradigm in G protein‐coupled receptor signalling through ITIMs. British Journal of Pharmacology 2012, 165 (6) , 1678-1687. https://doi.org/10.1111/j.1476-5381.2011.01510.x
    47. Giordano Lesma, Roberto Cecchi, Sergio Crippa, Paola Giovanelli, Fiorella Meneghetti, Manuele Musolino, Alessandro Sacchetti, Alessandra Silvani. Ugi 4-CR/Pictet–Spengler reaction as a short route to tryptophan-derived peptidomimetics. Organic & Biomolecular Chemistry 2012, 10 (45) , 9004. https://doi.org/10.1039/c2ob26301g
    48. Romano Di Fabio, Annalisa Pellacani, Stefania Faedo, Adelheid Roth, Laura Piccoli, Philip Gerrard, Rod A. Porter, Christopher N. Johnson, Kevin Thewlis, Daniele Donati, Luigi Stasi, Simone Spada, Geoffrey Stemp, David Nash, Clive Branch, Leanda Kindon, Mario Massagrande, Alessandro Poffe, Simone Braggio, Elisabetta Chiarparin, Carla Marchioro, Emiliangelo Ratti, Mauro Corsi. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorganic & Medicinal Chemistry Letters 2011, 21 (18) , 5562-5567. https://doi.org/10.1016/j.bmcl.2011.06.086
    49. David A. Perrey, Brian P. Gilmour, Scott P. Runyon, Brian F. Thomas, Yanan Zhang. Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2011, 21 (10) , 2980-2985. https://doi.org/10.1016/j.bmcl.2011.03.048
    50. Thierry Voisin, Aadil El Firar, Magali Fasseu, Christiane Rouyer-Fessard, Véronique Descatoire, Francine Walker, Valérie Paradis, Pierre Bedossa, Dominique Henin, Thérèse Lehy, Marc Laburthe. Aberrant Expression of OX1 Receptors for Orexins in Colon Cancers and Liver Metastases: an Openable Gate to Apoptosis. Cancer Research 2011, 71 (9) , 3341-3351. https://doi.org/10.1158/0008-5472.CAN-10-3473
    51. Thomas E. Scammell, Christopher J. Winrow. Orexin Receptors: Pharmacology and Therapeutic Opportunities. Annual Review of Pharmacology and Toxicology 2011, 51 (1) , 243-266. https://doi.org/10.1146/annurev-pharmtox-010510-100528
    52. John Gatfield, Catherine Brisbare‐Roch, Francois Jenck, Christoph Boss. Orexin Receptor Antagonists: A New Concept In CNS Disorders?. ChemMedChem 2010, 5 (8) , 1197-1214. https://doi.org/10.1002/cmdc.201000132
    53. Paul J. Coleman, John D. Schreier, Anthony J. Roecker, Swati P. Mercer, Georgia B. McGaughey, Christopher D. Cox, George D. Hartman, C. Meacham Harrell, Duane R. Reiss, Scott M. Doran, Susan L. Garson, Wayne B. Anderson, Cuyue Tang, Thomayant Prueksaritanont, Christopher J. Winrow, John J. Renger. Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat. Bioorganic & Medicinal Chemistry Letters 2010, 20 (14) , 4201-4205. https://doi.org/10.1016/j.bmcl.2010.05.047
    54. Pari Malherbe, Olivier Roche, Anne Marcuz, Claudia Kratzeisen, Joseph G. Wettstein, Caterina Bissantz. Mapping the Binding Pocket of Dual Antagonist Almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX 1 Antagonist SB-674042 and the Selective OX 2 Antagonist N -Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]- N -pyridin-3-ylmethyl-acetamide (EMPA). Molecular Pharmacology 2010, 78 (1) , 81-93. https://doi.org/10.1124/mol.110.064584
    55. P Hoever, S de Haas, J Winkler, R C Schoemaker, E Chiossi, J van Gerven, J Dingemanse. Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant. Clinical Pharmacology & Therapeutics 2010, 87 (5) , 593-600. https://doi.org/10.1038/clpt.2010.19
    56. Paul J. Coleman, John D. Schreier, Georgia B. McGaughey, Michael J. Bogusky, Christopher D. Cox, George D. Hartman, Richard G. Ball, C. Meacham Harrell, Duane R. Reiss, Thomayant Prueksaritanont, Christopher J. Winrow, John J. Renger. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2010, 20 (7) , 2311-2315. https://doi.org/10.1016/j.bmcl.2010.01.138
    57. Thierry Sifferlen, Christoph Boss, Emmanuelle Cottreel, Ralf Koberstein, Markus Gude, Hamed Aissaoui, Thomas Weller, John Gatfield, Catherine Brisbare-Roch, Francois Jenck. Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2010, 20 (5) , 1539-1542. https://doi.org/10.1016/j.bmcl.2010.01.070
    58. M. Laburthe, T. Voisin, A. El Firar. Orexins/hypocretins and orexin receptors in apoptosis: a mini‐review. Acta Physiologica 2010, 198 (3) , 393-402. https://doi.org/10.1111/j.1748-1716.2009.02035.x
    59. Paul J Coleman, John J Renger. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opinion on Therapeutic Patents 2010, 20 (3) , 307-324. https://doi.org/10.1517/13543770903567085
    60. Xin Qi, John Astle, Thomas Kodadek. Rapid identification of orexin receptor binding ligands using cell-based screening accelerated with magnetic beads. Mol. BioSyst. 2010, 6 (1) , 102-107. https://doi.org/10.1039/B915611A
    61. Wei Wang, Eberhardt Herdtweck, Alexander Dömling. Polycyclic indole alkaloid-type compounds by MCR. Chem. Commun. 2010, 46 (5) , 770-772. https://doi.org/10.1039/B917660H
    62. Teri M. Furlong, Daniel M. L. Vianna, Lu Liu, Pascal Carrive. Hypocretin /orexin contributes to the expression of some but not all forms of stress and arousal. European Journal of Neuroscience 2009, 30 (8) , 1603-1614. https://doi.org/10.1111/j.1460-9568.2009.06952.x
    63. Christian Gege, Christian D. Klein. Frontiers in Medicinal Chemistry 2009—a Summary of the Meeting at Heidelberg University. ChemMedChem 2009, 4 (8) , 1371-1376. https://doi.org/10.1002/cmdc.200900151
    64. David B. Whitman, Christopher D. Cox, Michael J. Breslin, Karen M. Brashear, John D. Schreier, Michael J. Bogusky, Rodney A. Bednar, Wei Lemaire, Joseph G. Bruno, George D. Hartman, Duane R. Reiss , C. Meacham Harrell, Richard L. Kraus, Yuxing Li, Susan L. Garson, Scott M. Doran, Thomayant Prueksaritanont, Chunze Li, Christopher J. Winrow, Kenneth S. Koblan, John J. Renger, Paul J. Coleman. Discovery of a Potent, CNS‐Penetrant Orexin Receptor Antagonist Based on an N , N ‐Disubstituted‐1,4‐diazepane Scaffold that Promotes Sleep in Rats. ChemMedChem 2009, 4 (7) , 1069-1074. https://doi.org/10.1002/cmdc.200900069
    65. Christopher D. Cox, Georgia B. McGaughey, Michael J. Bogusky, David B. Whitman, Richard G. Ball, Christopher J. Winrow, John J. Renger, Paul J. Coleman. Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding. Bioorganic & Medicinal Chemistry Letters 2009, 19 (11) , 2997-3001. https://doi.org/10.1016/j.bmcl.2009.04.026

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect